Table 1 Panel of selected HDAC inhibitors and controls.

From: Sirtuin inhibitors reduce intracellular growth of M. tuberculosis in human macrophages via modulation of host cell immunity

HDAC inhibitor

Target HDAC

IC501

Phenylbutyrate2

HDAC1, 2, 3 and 8

0.4–5.5 mM

Entinostat

HDAC1 and 3

0.51 and 1.7 µM

Apicidin

HDAC7 and 8

0.1–10 µM

Romidepsin

HDAC1 and 2

36 and 47 nM

Tubastatin A

HDAC6

15 nM

Tubacin

HDAC6

4 nM

Valproic acid

HDAC1 and 2

400 µM and 2 mM

Mocetinostat

HDAC1, 2, 3 and 11

0.15 µM

MI192

HDAC2 and 3

16 and 30 nM

Selisistat/EXS27

SIRT1

0.038 µM

AGK2

SIRT2

3.5 µM

Tenovin

SIRT1 and 2

10 and 21 µM

Suramin

SIRT1, 2 and 5

0.297 and 1.15 µM

Salermide

SIRT1 and 2

56.25 and 15.62 µM

Sirtinol

SIRT1 and 2

131 and 38 µM

Cambinol

SIRT1 and 2 (3)

56 and 59 µM

Givinostat

HDAC1 and 3

198 and 157 nM

Vorinostat/SAHA

Broad-spectrum

~ 10 nM

Belinostat

Broad-spectrum

27 nM

Panabinostat

Broad-spectrum

5 nM

Trichostatin A/TSA

Broad-spectrum

~ 1.8 nM

Dacinostat

Broad-spectrum

32 nM

Decitabine

DNMT inhibitor3

250–500 nM

  1. 1 IC50 estimated in cell-free or cell-based assays as provided by the manufacturers.
  2. 2 Phenylbutyrate is used as internal HDAC inhibitor control.
  3. 3 DNA methyltransferase (DNMT)-inhibiting cytosine nucleoside analogue.
Back to article page